OncoCyte Corporation (OCX) Social Stream
ONCOCYTE CORP (OCX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering ONCOCYTE CORP.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 3 | $11 | $5 | $7.75 | $3.36 | 130.65% |
| 2021-11-10 | 4 | $11 | $5 | $7.5 | $3.36 | 123.21% |
| 2021-12-16 | 3 | $11 | $5 | $7.666 | $3.36 | 128.15% |
| 2022-01-06 | 5 | $11 | $3.1 | $6.525 | $3.36 | 94.2% |
| 2022-02-01 | 5 | $11 | $3.1 | $5.55 | $3.36 | 65.18% |
| 2022-03-17 | 5 | $11 | $1.8 | $5.225 | $3.36 | 55.51% |
| 2022-04-01 | 5 | $11 | $1.8 | $4.95 | $3.36 | 47.32% |
| 2022-05-16 | 5 | $11 | $1.4 | $4.85 | $3.36 | 44.35% |
| 2022-06-06 | 5 | $5 | $1.25 | $2.912 | $3.36 | -13.33% |
| 2022-08-11 | 6 | $4 | $1.25 | $2.35 | $3.36 | -30.06% |
| 2022-08-17 | 6 | $4 | $1.25 | $2.37 | $3.36 | -29.46% |
| 2022-09-01 | 6 | $4 | $1.15 | $2.35 | $3.36 | -30.06% |
| 2022-11-01 | 5 | $4 | $0.9 | $2.3 | $3.36 | -31.55% |
| 2022-11-11 | 5 | $4 | $0.9 | $2.16 | $3.36 | -35.71% |
| 2022-11-14 | 5 | $4 | $0.9 | $2.06 | $3.36 | -38.69% |
| 2022-11-18 | 5 | $4 | $0.5 | $1.96 | $3.36 | -41.67% |
| 2022-12-07 | 5 | $4 | $0.5 | $1.46 | $3.36 | -56.55% |
| 2023-04-10 | 5 | $4 | $0.4 | $1.36 | $3.36 | -59.52% |
| 2023-05-01 | 3 | $4 | $0.4 | $1.337 | $3.36 | -60.21% |
| 2023-05-14 | 3 | $4 | $0.3 | $1.287 | $3.36 | -61.7% |
| 2023-06-01 | 3 | $0.45 | $0.3 | $0.383 | $3.36 | -88.6% |
| 2023-08-10 | 3 | $8 | $4.25 | $6.083 | $3.36 | 81.04% |
| 2023-08-15 | 3 | $8 | $3.5 | $5.25 | $3.36 | 56.25% |
| 2023-08-24 | 4 | $8 | $3.5 | $5.187 | $3.36 | 54.38% |
| 2023-09-01 | 4 | $5 | $3.5 | $4.187 | $3.36 | 24.61% |
| 2023-11-09 | 4 | $5 | $3.5 | $4.025 | $3.36 | 19.79% |
| 2023-12-01 | 4 | $5 | $3 | $3.9 | $3.36 | 16.07% |
The Trend in the Analyst Price Target
OCX's average price target has moved down $3.81 over the prior 30 months.
OCX reports an average of 340.37% for its upside potential over the past 43 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-04-10 | 4 | 4 | 0.4 | 1.170 | 0.350 | 234.29% |
| 2023-04-10 | 4 | 4 | 0.4 | 1.360 | 0.350 | 288.57% |
| 2023-05-14 | 3 | 4 | 0.3 | 1.287 | 0.252 | 410.71% |
| 2023-11-13 | 4 | 5 | 3.0 | 3.900 | 2.757 | 41.46% |
| 2023-12-01 | 4 | 5 | 3.0 | 3.900 | 3.880 | 0.52% |
OCX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.25 | 1 | 1 | 2 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 24 months, OCX's average broker recommendation rating worsened by 0.92.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, ONCOCYTE CORP's average analyst price target is higher than 113.19% of them.
- OCX has a lower variance in analysts' estimates than -2855.99% of all US stocks.
- ONCOCYTE CORP's number of analysts covering the stock is higher than 702.12% of Healthcare stocks.
- ONCOCYTE CORP's upside potential (average analyst target price relative to current price) is greater than 939.53% of stocks in the small market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ONCOCYTE CORP are ABIO, TKNO, and KROS.
View All Top Stocks by Price Target
Is OCX a Buy, Hold or Sell? See the POWR Ratings now!